# UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/URGN/urogen-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: URGN
Company: UroGen Pharma
Source: UroGen Pharma
Published: 2026-03-06 21:10 EST
Original Source URL: https://investors.urogen.com
## Summary

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 11 new

## Article Body
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 11 new
## Recent Company News
- 2026-06-02 12:00 EST — [UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution](https://biopharmsignal.com/news/URGN/urogen-announces-agreement-resolving-patent-litigation-relating-to-jelmytor-mitomycin-for-pyelocalyceal-solution) — Source: UroGen Pharma
- 2026-06-01 20:10 EST — [UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: UroGen Pharma
- 2026-05-15 12:00 EST — [UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC](https://biopharmsignal.com/news/URGN/urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade-intermediate-risk-nmibc) — Source: UroGen Pharma
- 2026-05-13 12:00 EST — [ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial](https://biopharmsignal.com/news/URGN/zusduri-median-duration-of-response-still-not-reached-with-64-5-36-month-duration-of-response-in-the-pivotal-envision-trial) — Source: UroGen Pharma
- 2026-05-07 12:00 EST — [UroGen Pharma to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/URGN/urogen-pharma-to-present-at-upcoming-investor-conferences) — Source: UroGen Pharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)